Content type: News


Jacopo Andreose is the new Chief Executive Officer of Angelini Pharma

Angelini Industries welcomes Jacopo Andreose as Chief Executive Officer of Angelini Pharma.

Jacopo Andreose has more than 20 years of experience in senior roles in the pharmaceutical industry: he comes from Gilead Sciences - where he served as Senior Vice President, Intercontinental Region, with direct responsibility for the business in Asia, Latin America, the Middle East, Africa, and Eastern Europe - and he previously worked at GlaxoSmithKline/ViiV Healthcare, Bristol-Myers Squibb and Abbott, holding increasing strategic and operational roles in Italy, the United States, Europe, and Asia.

Jacopo is joining Angelini Pharma with a mission to significantly boost the company's development, on the one hand by continuing to strengthen our historical foothold in consumer healthcare, and on the other by seizing all opportunities arising from our commitment in the therapeutic area of brain health” said Sergio Marullo di Condojanni, CEO of Angelini Industries. “Our investment in Ontozry - the Group's largest ever - has the transformational value we need and we are confident that Jacopo will be able to make it a reality by seizing its full potential, in the best interest of both patients and the company.

Jacopo Andreose said: “I am delighted for the opportunity to be part of Angelini Pharma, a company that combines tradition and established trust from patients and healthcare professionals in Italy and abroad with a strong drive for innovation. I want to thank Sergio and Thea Paola for their trust, and I know I can count on the team's support in continuing the mission of providing patients and their loved ones with innovative solutions to improve health and quality of life.